Recent Finacing
Recent Raise
Atavistik Bio is a clinical-stage biotech developing therapies for hereditary hemorrhagic telangiectasia (HHT) and JAK2-mutant myeloproliferative neoplasms.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors
See the team members at Atavistik Bio.
